AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer

NATICK, Mass., May 17, 2021 -- (Healthcare Sales & Marketing Network) -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today that the US Food and Drug... Biopharmaceuticals, Oncology, FDA AffyImmune Therapeutics, immunotherapy, Thyroid Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news